How sites work with external recruitment vendors

A coordinator at a small research site spends three months getting authorized to use a vendor-run referral portal. When the portal finally goes live, the first batch of patient leads arrives in a CSV file. The names are real and the contact details are correct, but the inclusion and exclusion criteria the vendor used do not match the protocol's most recent amendment. Roughly forty percent of the leads will be screen failures (people who would not pass the site's formal eligibility review, in industry shorthand) before the coordinator opens the second page of the spreadsheet.

That gap is what every site fears when an external recruitment vendor (a third-party company that finds and routes potential study participants to the research site) enters the picture. Working with one does not have to look like this. The sites that get the most out of the relationship decide, before the vendor is signed, what the vendor is and is not allowed to control. They protect what belongs to the site (the patient relationship, the eligibility decision, the data flow, the protocol fidelity) and let the vendor do what it is genuinely good at: reach, awareness, top-of-funnel screening. They stay in the driver's seat.

Why sites bring in external recruitment vendors in the first place

Most research sites do not start a study expecting to use an external recruitment vendor. The plan, when the contract is signed, is usually to run recruitment in-house: physician referrals from within the network, database searches, posters in waiting rooms, and local outreach. For many studies that is enough.

For others it is not. Some studies need patients with rare conditions whose local prevalence (how common the condition is in a given population) is too low for the site to fill quotas from its existing pool. Others have aggressive enrollment timelines set by the sponsor and the contract research organization (CRO) running the trial, and missing those timelines triggers financial penalties or site replacement. Still others need participant populations the site does not naturally see.

In each case the site faces the same choice: keep recruiting in-house and hope volume catches up, or bring in an external recruitment vendor that can run paid media, targeted online outreach, call-center pre-screening, and referral pipelines that go beyond what the site can run on its own.

Why this matters is well covered in The Recruitment Struggle Is Real: What Today's Sites Need to Compete. The decision to bring in a vendor is rarely a sign that the site is failing. It is usually a sign that the protocol is harder than the contract suggested.

What a good vendor does, and what a good vendor does not do

A useful external recruitment vendor expands the top of the recruitment funnel. It runs awareness campaigns the site does not have the budget or technical setup to run on its own. It maintains call-center capacity for inbound questions from interested members of the public. It does early-stage pre-screening, asking a structured set of questions to filter out clearly ineligible respondents before any are routed to the site. It generates qualified referrals: potential participants who have passed the vendor's initial questions and appear likely to meet at least the most visible parts of the protocol.

A useful vendor does not make final eligibility decisions, does not collect informed consent, does not handle randomization, and does not own the patient relationship once a participant is referred to the site. Those four functions sit with the site's research team, because each carries regulatory obligations the site is legally and operationally responsible for under the protocol and under United States clinical research regulations.

This division of labor is the underlying point of How qualified participant referrals solve the site recruitment problem. When a vendor proposes a scope of work that crosses any of the four boundaries (running an eligibility verification visit, collecting consent on behalf of the site, holding patient data in a system the site cannot access, communicating directly with referred patients after the handoff), the site should push back. Those are not vendor functions.

The handoff is where control gets lost or kept

The single most consequential moment in a vendor relationship is the handoff: the point at which a person identified by the vendor as a potential participant moves from the vendor's pre-screening into the site's formal screening. Done well, the handoff is invisible to the patient and useful to the site. Done badly, it produces the spreadsheet-of-screen-failures scenario described at the top of this article.

Three things keep the handoff clean. The first is a clearly defined pre-screening protocol. The vendor's pre-screening questions should be built from the same inclusion and exclusion criteria the site uses, with the same medication exclusions, the same laboratory thresholds, and the same age, condition, and prior-care requirements. If the protocol is amended, the vendor's questions are amended on the same timeline.

The second is a structured data handoff. The site needs the vendor's pre-screening answers in a format it can review before the patient arrives, ideally integrated into the site's clinical trial management system (the software sites use to track participants, visits, and study data, often shortened to CTMS).

The third is a clear point of escalation. When a pre-screened patient turns out to be ineligible at the formal screening visit, the site needs a fast way to send feedback to the vendor so the pre-screening questions can be adjusted before the next batch arrives.

Pre-screening done well is not just a vendor question; Pre-Screening Smarter: How Technology Reduces Screen Failures at Sites covers the same ground from the site's internal angle, and the principles transfer. Sites that lock these three things down before the contract is signed avoid most of the friction that defines difficult vendor relationships.

Protecting the patient relationship and the site's reputation

The patient does not know, and does not need to know, which company runs the call center. What the patient experiences is one continuous relationship: a first conversation about a study, a follow-up with the research site, a screening visit, and a decision. If the vendor and the site speak in different voices or contradict each other on the basics of what the study involves, that continuity breaks. The patient loses confidence, and the site loses the referral.

Protecting the patient experience means setting expectations with the vendor on tone, accuracy, and accessibility. Materials sent to interested patients should be reviewed and approved by the site's principal investigator (the physician responsible for the conduct of a study at a given site). Call-center scripts should be aligned with what the coordinator will say at screening. Commitments the vendor makes about visit length, reimbursement, or what the study involves should be commitments the site can keep.

It also means protecting privacy. The vendor will collect personal health information about people who may or may not become study participants. Under the Health Insurance Portability and Accountability Act (HIPAA, the U.S. law that protects the privacy of personal health information), that data flow has to be governed by a written agreement that specifies what the vendor can collect, how long it can hold the data, who can see it, and what happens to it when the engagement ends. Sites that skip this conversation tend to find out about it during an audit.

Data, dashboards, and reporting that work for the site

Most external recruitment vendors build their reporting around the sponsor and the CRO. The sponsor pays for the campaign, so the sponsor sees the dashboards: referrals by week, conversion rates by channel, cost per randomized participant (the cost to bring in one person who is then formally assigned to a study group). That is operational truth at the program level.

The site needs operational truth at the site level. It needs to see, in close to real time, how many referrals are in the queue, how many have been pre-screened, how many have been routed to the site, how many have appointments scheduled, and where each one sits in the funnel between first contact and randomization. Without that view, the site is reacting to inbound referrals instead of planning around them.

Most sites already have part of this view in their own systems, as covered in Clinical Trial Management Systems: The Backbone of Site Operations, but the vendor's data has to flow into it cleanly for the view to be useful.

When negotiating data access, the site should ask for three things: a site-level dashboard updated at least daily showing the funnel from referral to randomization; an export function that lets the site pull underlying data into its own systems; and clarity on what happens to the data after the study ends. A vendor that resists these requests is signaling that its operating model is built around sponsor visibility, not site visibility. That is a legitimate business choice for the vendor, but it is not a fit for a site that wants to stay in control of its own recruitment performance.

How sites should evaluate and govern the vendor relationship

A site evaluating an external recruitment vendor often sees two numbers first: the referrals the vendor expects to deliver and the cost per referral. Both matter, and neither is enough.

The harder questions are about quality and fit. What percentage of the vendor's pre-screened referrals typically pass formal site screening? What percentage of those screened-in patients reach randomization? In what therapeutic areas (broad categories of disease or condition, such as cardiology, oncology, neurology, or rare disease) does the vendor have a recent track record, and is the site's therapeutic area on that list? How does the vendor handle privacy, data security, and the written agreements that govern personal health information? What references can the vendor provide from sites of comparable size?

The quality side of the answer feeds the same site-performance metrics covered in Building Sponsor Trust: Metrics That Show Site Performance.

Governance matters as much as selection. Once the vendor is on board, the site should set a regular cadence of working meetings (weekly during peak recruitment, monthly during steady state), with shared metrics on referral volume, quality, conversion, and any feedback on the pre-screening process. A vendor that treats the site as a passive recipient of leads will not improve over the course of the study. A vendor that adjusts its targeting based on site feedback will.

How DecenTrialz fits the picture for research sites

DecenTrialz is a United States clinical trial recruitment, pre-screening, and participant management platform built around the boundary described in this article. The platform uses AI-assisted participant matching (software that uses pattern recognition to identify people who appear to meet a study's inclusion and exclusion criteria) and registered-nurse-led pre-screening conversations to review interested participants before they are referred to a research site. The site's research team handles the formal eligibility assessment, informed consent (a federally required process in which a participant is told what a study involves before agreeing to take part), enrollment, and all ongoing study procedures under United States clinical research regulations.

For sites, that boundary is the practical answer to the staying-in-control question. The platform contributes top-of-funnel reach and registered-nurse-led pre-screening. The site contributes everything that has to stay with the site: clinical judgment, regulatory accountability, the patient relationship after referral, and the decision about who enrolls. Sites that want to look into how the model fits their study mix can start at DecenTrialz.

External recruitment vendors are not the problem and not the solution on their own. They are a recruitment lever sites can pull when in-house outreach is not enough, and the value the vendor adds depends almost entirely on how the relationship is structured before the first referral arrives. Sites that define the pre-screening protocol, the handoff, the data flow, the patient experience, and the governance cadence up front keep control of the work. The driver's seat is available; it just has to be claimed early. Sites can start at decentrialz.com.